Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsResearch chemical 2C-H
Research chemicalPsychedelicPrecursor2C phenethylamine

2C-H

Also known as 2,5-DMPEA

2C-H (2,5-dimethoxyphenethylamine) is the unsubstituted parent of the 2C phenethylamine family. It is largely inactive as a psychedelic in humans and is chiefly encountered as a synthetic precursor to compounds like 2C-B and 2C-I.

01 Overview

2C-H was described by Alexander Shulgin, who reported it produced essentially no psychoactive effect at tested doses, likely because it is rapidly metabolised by monoamine oxidase before reaching the CNS. Its main significance is as a chemical intermediate for the wider 2C series.

Because it is functionally inactive, human data are effectively absent and any subjective reports are unreliable. It is discussed here as a family reference rather than a recreational agent.

02 Mechanism

A 5-HT2A partial agonist scaffold, but the unhindered position leaves it a favoured MAO substrate, so oral doses are degraded before appreciable central 5-HT2A activation occurs.

03 Dosing

TierDoseRouteNotes
Reported threshold100–200 mgOralShulgin reported little to no effect even at high doses.

04 Effects

EffectMagnitudeEvidence
Minimal psychoactivityMost reports describe no clear psychedelic effect, consistent with rapid MAO metabolism.sub-perceptualAnecdotal
Mild stimulationOccasional reports of faint restlessness, not reliably distinguishable from placebo.slightUnconfirmed

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
NauseaGastric upset reported with 2C-series phenethylamines generally.MildUnknownAnecdotal
Unknown toxicityNo safety pharmacology exists; purity of research-grade material is unverifiable.ModerateUnknownUnconfirmed

07 References

PiHKAL: A Chemical Love Story (2C-H entry)Shulgin & Shulgin, 1991

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.